Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Net Cash Flow (2016 - 2025)

Standard Biotools (LAB) has disclosed Net Cash Flow for 16 consecutive years, with -$29.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 50.65% to -$29.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$80.6 million, a 161.17% decrease, with the full-year FY2024 number at $117.1 million, up 492.19% from a year prior.
  • Net Cash Flow was -$29.0 million for Q3 2025 at Standard Biotools, down from $6.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $235.9 million in Q1 2024 to a low of -$62.5 million in Q3 2023.
  • A 5-year average of $3.3 million and a median of -$13.9 million in 2022 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 2546.35% in 2022; the steepest drop was 906.53% in 2022.
  • Standard Biotools' Net Cash Flow stood at -$850000.0 in 2021, then soared by 2546.35% to $20.8 million in 2022, then tumbled by 235.52% to -$28.2 million in 2023, then plummeted by 52.06% to -$42.9 million in 2024, then skyrocketed by 32.34% to -$29.0 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Net Cash Flow are -$29.0 million (Q3 2025), $6.9 million (Q2 2025), and -$15.7 million (Q1 2025).